Why the study?
While CaMKIIδ is implicated in myocardial infarction- and pressure overload-induced remodeling, its role in volume overload-induced adverse myocardial remodeling and heart failure progression had not been explored.
Does genetic deletion of CaMKIIδ prevent adverse myocardial remodeling and mortality in mice with volume overload-induced heart failure?
Does genetic deletion of CaMKIIδ prevent adverse myocardial remodeling and mortality in mice with volume overload-induced heart failure?
CaMKIIδ signaling appears dispensable for the progression of volume overload-induced maladaptive cardiac remodeling, suggesting its inhibition may not be a useful therapeutic approach in this context.
CaMKIIδ deletion does not mitigate volume-overload remodeling in mice; leaves open its therapeutic relevance in other heart failure models.
Calcium/calmodulin-dependent protein kinase type II delta (CaMKIIδ), the predominant CaMKII isoform expressed in the heart, has been implicated in the progression of myocardial infarction- and pressure overload-induced pathological remodeling. However, the role of CaMKIIδ in volume overload (VO) has not been explored. We have previously reported an activation of CaMKII during transition to HF in long-term VO. Here, we address whether CaMKIIδ is critically involved in the mortality, myocardial remodeling, and heart failure (HF) progression in response to VO. CaMKIIδ knockout (δ-KO) and wild-type (WT) littermates were exposed to aortocaval shunt-induced VO, and the progression of adverse myocardial remodeling was assessed by serial echocardiography, histological and molecular analyses. The mortality rates during 10 weeks of VO were similar in δ-KO and WT mice. Both genotypes displayed comparable eccentric myocardial hypertrophy, altered left ventricle geometry, perturbed systolic and diastolic functions after shunt. Additionally, cardiomyocytes hypertrophy, augmented myocyte apoptosis, and up-regulation of hypertrophic genes were also not significantly different in δ-KO versus WT hearts after shunt. Therefore, CaMKIIδ signaling seems to be dispensable for the progression of VO-induced maladaptive cardiac remodeling. Accordingly, we hypothesize that CaMKIIδ-inhibition as a therapeutic approach might not be helpful in the context of VO-triggered HF.
No takes yet. Share an insight, caveat, or question.
Mohamed et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: